经导管动脉栓塞治疗胰十二指肠切除术后晚期出血

目的 观察经导管动脉栓塞(TAE)治疗胰十二指肠切除术(PD)后晚期(术后7天以上)出血的效果。方法 回顾性收集12例因PD术后晚期出血而接受TAE并存在C级胰瘘患者,观察血管造影表现,记录栓塞方法及其效果、TAE后并发症及其后2周胰瘘变化等。结果 12例中,6例存在假性动脉瘤,其中3例见于肝固有动脉或肝总动脉、3例见于胃十二指肠动脉;6例消化道出血,3例来源于胰十二指肠下动脉、3例源自胃十二指肠动脉假性动脉瘤。对6例以弹簧圈、6例以弹簧圈+明胶海绵颗粒进行栓塞;12例均有效止血,治疗后均未再发出血。TAE后4例发热(最高体温39.1℃)、2例腹痛;5例肝功能损伤主要表现为转氨酶升高;均经对症治疗后好转。TAE后2周,5例胰瘘分级降为B级、3例降为A级(即生化瘘),4例仍见C级胰瘘。结论 以单一弹簧圈或联合明胶海绵颗粒行TAE治疗PD术后晚期出血安全、有效,且能促进胰瘘愈合。     

经皮肾镜取石术后肾出血的选择性肾动脉造影和栓塞治疗

目的 观察经皮肾镜取石术(PCNL)后肾出血的DSA影像学表现及超选择性动脉栓塞治疗的疗效.方法 收集PCNL术后肾出血经保守治疗无效患者12例,经选择性肾动脉造影检查,明确诊断后行超选择性肾动脉栓塞治疗,评价疗效. 结果 12例患者中,单纯假性动脉瘤8例,假性动脉瘤伴动静脉瘘2例,假性动脉瘤伴对比剂外溢2例,选用明胶海绵、真丝线段、聚乙烯醇微粒和微弹簧圈等栓塞材料成功进行栓塞,随访6个月均未发现再出血.2例患者出现栓塞后综合征,1例血清肌酐略升高,给予对症处理后症状逐渐好转.结论 选择性肾动脉造影可明确诊断PCNL术后肾出血;栓塞治疗迅速、安全有效、并发症少、可最大限度保护肾功能,是PCNL术后肾出血保守治疗无效的首选治疗方法.     

Glubran-2胶经导管动脉栓塞治疗经皮肝穿刺胆道引流术后出血

目的 观察以Glubran-2胶经导管动脉栓塞(TAE)治疗经皮肝穿刺胆道引流术(PTCD)后出血的效果。方法 回顾性分析17例接受Glubran-2胶TAE治疗PTCD后出血的患者,观察技术成功率、临床成功率及并发症情况;比较TAE后当日与次日红细胞(RBC)及血红蛋白(Hb)差异;比较TAE前与TAE次日及第2日、TAE前与TAE后第4日谷丙转氨酶(GPT)差异。结果 17例均经TAE成功栓塞责任血管,技术成功率及临床成功率均为100%;均未出现肝脓肿、败血症及肺栓塞等严重并发症。TAE后当日与次日,RBC及Hb差异均无统计学意义(P均>0.05);TAE前GPT低于TAE后次日及第2日(P<0.05),TAE前与TAE后第4日GPT差异无统计学意义(P>0.05)。结论 以Glubran-2胶行TAE治疗PTCD后出血安全、有效。     

介入栓塞术治疗前列腺动脉与阴茎背动脉共干良性前列腺增生

目的 观察采用介入栓塞术治疗前列腺动脉（PA）与阴茎背动脉共干的良性前列腺增生（BPH）的效果。方法 回顾性分析29例接受介入栓塞术的PA与阴茎背动脉共干的BPH患者。结果 29例中,对12例以微导管超选择进入PA,以小颗粒（直径150~300 μm）PVA进行常规栓塞,术后前列腺实质染色消失,阴茎背动脉良好,患者症状明显改善,无阴茎相关并发症发生。17例未能超选择进入PA,对2例以小颗粒PVA进行常规栓塞,术后排尿困难等症状均明显改善,但均发生阴茎缺血坏死并发症;3例以大颗粒PVA（直径350~560 μm）栓塞,术后未出现阴茎并发症,但排尿困难等症状改善不理想;12例以橡皮条暂时结扎阴茎根部再以小颗粒PVA栓塞,术后排尿困难等症状明显改善,未出现阴茎缺血、坏死并发症。结论 对于前列腺动脉与阴茎背动脉共干的BPH,介入栓塞术治疗效果较好,应根据患者具体情况选择和调整术式。     

临界可切除肝癌行肝动脉灌注化疗联合肝动脉栓塞术转化治疗的疗效

背景与目的 对于临界可切除的原发性肝癌,目前我国原发性肝癌诊疗指南（2022年版）推荐仍是肝动脉插管化疗栓塞术（TACE）、外科手术切除或系统抗肿瘤治疗。当前原发性肝癌的术前转化治疗已经取得了很大的进展,但对于具体转化治疗方案尚在探索中。本研究探讨临界可切除肝癌行FOLFOX方案的肝动脉灌注化疗（HAIC）联合肝动脉栓塞术（TAE）局部转化治疗的真实世界疗效。方法 收集2019年4月—2022年2月采用FOLFOX方案的HAIC联合TAE转化治疗的22例临界可切除（CNLC分期Ⅱb期）原发性肝癌患者的临床资料,根据改良实体瘤疗效评价（mRECIST）标准评估肿瘤客观缓解率（ORR）、疾病控制率（DCR）,分析转化手术切除率和术后标本的病理缓解率以及转化治疗后手术与未手术患者的预后情况。结果 22例患者均完成HAIC联合TAE治疗,主要不良反应包括上腹痛、低热、短期的肝功能损害等,但没有发生不可逆的严重并发症。转化治疗后,肿瘤ORR、DCR分别为63.6%、86.3%,但有3例（13.6%）患者出现肿瘤进展。转化治疗结束后14例患者行肝癌手术切除,转化手术切除率为63.6%,手术顺利,均能达到R₀切除,无术后死亡病例。术后病理检查有10例（71.4%）为主要病理缓解（MPR）,但无1例能达到完全病理缓解（CPR）。14例手术患者的无复发生存期平均为14.7个月;手术患者的总生存期明显优于未手术患者（22.7个月vs. 13.2个月,P=0.018）。结论 HAIC联合TAE转化治疗对于临界可切除肝癌具有良好的耐受性,是安全可行的,能取得较高ORR、DCR和转化手术切除率。虽然大多数术前转化治疗后能达到MPR,但CPR较低,手术切除仍是肝癌转化治疗后患者获得长期生存的关键。     

经导管栓塞联合射频消融对兔VX2肝肿瘤的干预效果

目的 探讨经导管动脉栓塞术（TAE）联合射频消融（RFA）对兔VX2肝肿瘤的干预效果。方法 将兔VX2肝肿瘤模型分为4组,每组15只。对TACE+RFA组于TACE治疗15 min后行RFA,TAE+RFA组TAE治疗15 min后行RFA,RFA组仅给予RFA,TACE组仅给予TACE。分别于术前1天及术后3、7天检测血清天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）,术后7天检测肿瘤生长率、肿瘤坏死率及Suzuki评分;术后1、3、7天采用免疫组织化学法检测坏死区或凝固区周围肝组织热休克蛋白70（HSP70）表达,计算肝细胞凋亡指数及增殖指数。结果 TACE+RFA组术后3、7天血清ALT、AST水平均高于其他3组（P均<0.05）。术后7天,TACE+RFA组Suzuki评分高于其他3组,TACE+RFA组、TAE+RFA组肿瘤生长率低于RFA组和TACE组、肿瘤坏死率高于RFA组和TACE组（P均<0.05）。4组术后1、3、7天坏死区或凝固区周围肝组织HSP70表达均逐渐升高,TACE+RFA组术后1、3、7天均高于其他3组,术后1、3天TAE+RFA组均高于TACE组和RFA组（P均<0.05）。4组术后1、3、7天坏死区或凝固区周围肝细胞凋亡指数均逐渐降低,TACE+RFA组术后1、3、7天均高于其他3组,TACE组术后1、3天均高于TAE+RFA组、RFA组（P均<0.05）。4组术后3天肝细胞增殖指数均高于术后1、7天,TAE+RFA组术后1、3、7天均高于其他3组,RFA组术后1、3天均高于TACE+RFA组和TACE组（P均<0.05）。结论 TACE+RFA、TAE+RFA抑制兔VX2肝肿瘤生长效果优于单独应用TACE、RFA;TAE+RFA对肝损伤更小,促进肝细胞增殖、抑制其凋亡的效果更好。     

腹部增强CT诊断及经导管动脉栓塞治疗自发性腹膜后血肿

目的 评估腹部增强CT诊断及经导管动脉栓塞治疗自发性腹膜后血肿(SRH)的价值。方法 回顾性分析7例SRH患者,4例经腹部增强CT、1例经平扫CT、2例经超声诊断;均通过造影明确责任动脉后予以经导管动脉栓塞治疗;记录总造影用时,即首次造影与末次造影之间的时间间隔,以及治疗效果。结果 7例SRH中,6例造影可见明确责任动脉,均成功予以栓塞,随访至术后30天,病情均稳定;1例未见明确责任动脉,经内科保守治疗后病情稳定。4例经增强CT诊断SRH总造影用时32~60 min、中位用时47.5 min,其余3例总造影用时36~80 min、中位用时63.0 min。结论 腹部增强CT有助于诊断SRH及显示责任动脉、提高治疗效果;经导管动脉栓塞可有效治疗SRH。     

可切除肝细胞癌合并门静脉癌栓的外科治疗

背景与目的 对于肝细胞癌（HCC）合并门静脉癌栓（PVTT）患者而言,手术切除率低,复发率高,预后较差,其治疗方式目前仍有很多争议。笔者总结可切除HCC合并PVTT的外科治疗经验,比较手术与肝动脉化疗栓塞术（TACE）对此类患者的近远期疗效。方法 回顾性分析云南省临沧市人民医院2016年3月—2021年3月收治的39例可切除HCC合并PVTT患者的临床资料,其中23例患者施行手术治疗（手术组）,16例行TACE治疗（TACE组）。比较两组患者的相关临床资料与预后,并分析影响患者预后的因素。结果 手术组除1例肿瘤广泛侵犯仅取材活检,其余均完成手术,无手术死亡;19例示切缘阴性;2例术后肝功能不全,经人工肝及其他支持治疗痊愈出院。TACE组16例肝动脉超选、灌注、栓塞顺利;1例因肝动脉完全栓塞,术后3 d因急性肝衰竭救治无效死亡。手术组8例术后辅助TACE治疗,5例靶向治疗,其中1例I型PVTT患者手术后联合TACE等治疗后仍生存47个月。TACE组13例多次治疗,4例给靶向药物,其中1例II型PVTT患者TACE术后经过7次灌注化疗及栓塞仍然生存25个月。与TACE组比较,手术组住院时间延长、医疗成本增加、术后行TACE的例数更少、术后未做其他治疗的例数以及术后AFP恢复正常的例数更多（均P<0.05）。手术组与TACE组的中位生存期分别为16.2个月与9.5个月;0.5、1、2、3年生存率分别为65.2%、43.5%、34.8%、17.4%与46.7%、33.3.0%、13.3%、0。两组患者中位生存期与累积生存率差异均有统计学意义（均P<0.05）。单因素分析结果显示,PVTT分型、甲胎蛋白（AFP）水平、肿瘤大小、肿瘤数目与患者术后生存时间有关（均P<0.05）;多因素分析结果显示,治疗方式、PVTT分型、肿瘤直径、AFP水平是患者术后生存时间的独立影响因素（均P<0.05）。结论 PVTT分型、肿瘤直径、AFP水平直接影响HCC合并PVTT患者的术后生存,外科手术切除治疗效果明显好于TACE治疗,尤其是对于可切除HCC合并I/II型PVTT的患者,但治疗选择可能受患者意愿、经济因素等的限制。     

125I粒子植入术联合支气管动脉化疗栓塞治疗纵隔型肺癌和/或肿瘤纵隔淋巴结转移

目的 观察¹²⁵I粒子植入术联合经支气管动脉化疗栓塞(BACE)治疗纵隔型肺癌和/或肿瘤纵隔淋巴结转移的价值。方法 回顾性分析20例接受¹²⁵I粒子植入术联合BACE治疗的纵隔型肺癌和/或肿瘤纵隔淋巴结转移患者,观察术后肿瘤疗效反应、患者生存情况及生活质量等,评价联合治疗疗效。 结果 粒子植入术后患者均出现轻度不良反应,1例发生中度不良反应,未见重度不良反应。术后随访8~49个月,术后1个月卡诺夫斯基绩效状态量表(KPS)评分显著提高(P=0.019);术后6个月5例肿瘤完全缓解、9例部分缓解,4例疾病稳定,2例疾病进展,客观反应率为70.00%,局部控制率为90.00%;患者中位无进展生存期10.5个月,中位总生存期为20.5个月,总生存率45.00%。结论 ¹²⁵I粒子植入术联合BACE用于纵隔型肺癌和/或肿瘤纵隔淋巴结转移疗效和安全性均较好。     

氩氦刀局部冷冻消融联合全身疗法治疗晚期乳腺癌侵犯皮肤致破溃、出血

<正>乳腺癌发病率位居女性恶性肿瘤首位,发生转移后治愈率低,治疗应以改善症状、提高生活质量及延长生存期为主要目的。部分晚期乳腺癌体积巨大,常侵犯皮肤致其溃烂、感染,多伴反复出血及疼痛等,采用单纯全身治疗难以使皮肤破溃处愈合。本研究报告氩氦刀局部冷冻消融联合全身疗法治疗51例晚期巨大乳腺癌侵犯皮肤致破溃、出血的疗效。     

Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy

Background: The presence of skin involvement has been accepted as a relative contraindication to breast preservation because it is believed to be associated with an increased local failure rate. This study was conducted to assess the outcome of a carefully selected group of patients who presented with breast cancer involving the skin and who had breast conservation therapy (BCT) following neoadjuvant chemotherapy.Methods: Between 1987 and 1999, 33 patients with stage IIIB or IIIC breast cancer completed treatment consisting of four cycles of neoadjuvant chemotherapy, lumpectomy, radiation therapy, and consolidative chemotherapy. Clinicopathologic factors were analyzed and patients were followed for locoregional and distant recurrence.Results: Initial median tumor size was 7 cm. All patients had skin involvement, defined as erythema, skin edema, direct skin invasion, ulceration, or peau dorange. Following chemotherapy, median pathologic tumor size was 2 cm. Complete resolution of skin changes occurred in 29 patients (88%). At median follow-up time of 91 months in surviving patients, 26 patients (79%) were alive without evidence of disease. The 5-year, disease-free survival rate was 70%, and the 5-year overall survival rate was 78%. The actuarial ipsilateral breast cancer recurrence rate was 6% at 5 years.Conclusions: Patients who present with T4 breast cancer who experience tumor shrinkage and resolution of skin changes with neoadjuvant chemotherapy represent a select group of patients who can have BCT. These patients have favorable rates of long-term local control and survival. Mastectomy is not mandatory for all patients with breast cancer who present with skin involvement.Presented at the 57^th Annual Society for Surgical Oncology Cancer Symposium in New York City, New York, March 18–21, 2004     

Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer

Fifty patients with locally advanced breast cancer received regional chemotherapy delivered angiographically via the internal mammary artery and varying vessels supplying the lateral aspect of the breast. Thirty three patients received mitomycin C, methotrexate and mitoxantrone, and 17 patients received methotrexate and mitoxantrone only. There was no significant difference in clinical response between the two groups. However, in patients who received mitomycin C, severe local skin toxicity occurred in nine patients resulting in delay of further therapy and considerable morbidity. Mitomycin C should not be administered regionally in patients with locally advanced breast cancer.     

Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculocutaneous (TRAM) flap

Background: The management of stage III breast cancer is challenging; it often includes multimodal treatment with systemic therapy and/or radiation therapy and surgery. Immediate breast reconstruction has not traditionally been performed in these patients. We review the results of immediate transverse rectus abdominis musculocutaneous (TRAM) flap in 21 patients treated for stage III breast cancer. Methods: Data have been collected retrospectively on 21 patients diagnosed with stage III breast cancer between 1987 and 1994. All patients had mastectomy and immediate TRAM reconstruction. Thirteen patients received primary systemic therapy, 10 patients received postoperative consolidation radiotherapy to the operative site, and 3 patients received preoperative radiation. Results: Mean follow-up for the group was 26 months. Two patients died with disseminated disease: neither of them developed local disease recurrence in the operative site; 82% of the patients followed for at least two years are free of disease. Sixty-two percent of the patients received preoperative chemotherapy, the remaining patients received postoperative multiagent chemotherapy and/or radiation therapy. Two of the patients received autologous bone marrow transplants after their adjuvant therapy. Ten patients had postoperative radiotherapy for consolidation; three patients received preoperative radiation. Conclusions: Immediate TRAM reconstruction for stage III breast cancer is not associated with a delay in adjuvant therapy or an increased risk of local relapse. It facilitates wide resection of involved skin without skin grafting. Radiation therapy can be delivered to the reconstructed breast when indicated without difficulty. Breast reconstruction facilitates surgical resection of stage III breast cancer with primary closure and should be considered if the patient desires immediate breast reconstruction.Results of this study were presented at the 48th Annual Cancer Symposium of The Society of Surgical Oncology, Boston, Massachusetts, March 23–26, 1995.     

Pattern of care in locally advanced breast cancer: Focus on local therapy

Background and MethodsThe optimal treatment of locally advanced breast cancer (LABC) remains undetermined. We analyzed factors influencing local therapy in LABC in a pooled material including three large clinical series.ResultsOf a total of 787 patients, local therapy was given in 604, surgery in 184, radiotherapy in 69, and a combination thereof in 351. The use of local therapy was related to younger age, lower clinical T and N stage, no skin involvement and no progression during induction chemotherapy. The use of surgery was related to younger age, lower clinical T and N stage, no clinical skin involvement and response to induction chemotherapy. The use of postoperative radiotherapy was correlated with larger tumor size, higher number of positive lymph nodes, positive surgical margin, extracapsular lymph node extension, lymphatic vessel invasion and skin involvement.ConclusionsThe most frequent local therapy in LABC remains a combination of surgery and radiotherapy. Clinical and pathological characteristics influence the type of local treatment.     

Preoperative embolization of a giant benign phyllodes tumor: A case report and review of literature

Introduction and importancePhyllodes tumors (PT) account for less than 1% of all breast tumors. Giant PTs can lead to breast disfigurement, tumoral ulceration, and bleeding. Outright surgical excision can be challenging or unsafe. Preoperative transarterial embolization (TAE) has a role but data on its use in the management of PT is limited.Case presentationA 43-year-old female presented with a 28 cm fungating, necrotic, benign PT on her left breast that eventually developed tumoral bleeding leading to hemodynamic instability. Preoperative TAE controlled the bleeding and allowed the safe performance of mastectomy. A literature review of preoperative TAE of PTs is also presented including the addition of a chemotherapeutic agent in malignant types.Clinical discussionPTs are rare and comprise only 2.5% of all fibroepithelial breast lesions. Tumoral bleeding causing severe anemia is one of the most common presentations of massive (≥20 cm) PTs, especially when neglected. Indications for preoperative TAE include (1) to halt rapid tumor growth, (2) to control active/persistent tumoral bleeding, and (3) to shrink the tumor size and allow successful resection with negative margins, and avoidance of skin grafting. Post-TAE side effects include fever, chest pain, gradual/expanding tumor necrosis, decrease in tumor weight, and diminished tumoral abscess/discharge, and loss of tumoral vessel elasticity.ConclusionNeglected PTs can reach an alarming size. Preoperative TAE is a safe and effective method of controlling life-threatening tumoral hemorrhage and decreasing the size of PTs thereby allowing definitive resection while avoiding skin grafting and/or flap reconstruction.     

Surgical closure of chest wall in noninflammatory locally advanced breast carcinoma with ulceration of the skin

Patients with noninflammatory locally advanced breast cancer with ulceration of skin or muscle or parietal wall infiltration, better named "extended locally advanced breast cancer," may require cancer surgery and plastic reconstruction of the chest wall after multidisciplinary evaluation. The decision is made to improve quality of life, independently of prognosis, and severity of the disease. The aim of this study is to evaluate the best method for surgical closure of the chest wall and to check whether ablative surgery is an appropriate procedure in regards to the treatment of cancer. From October 1997 to June 2006, 27 patients with noninflammatory extended locally advanced breast cancer with ulceration of the skin, who were not candidate or did not respond to a neo-adjuvant treatment, underwent radical mastectomy and reconstructive surgery. Sixteen patients (59%) were affected by primary tumors of the breast, and eleven patients (41%) had local recurrence after mastectomy or conservative breast surgery. Two main techniques were used for breast reconstruction: transverse rectus-abdominis musculo cutaneous flap in 19 patients (70%), and a fasciocutaneous flap in eight patients (30%). The best procedure in each patient was chosen according to the extent of skin loss or previous radiotherapy to the chest wall. Fourteen patients (52%) died during the follow-up and the median length of survival was 16 months (range 3-79) in transverse rectus-abdominis musculo cutaneous group and 4 months (range 2-23) in fasciocutaneous flap group. The median length of follow-up after treatment for patients still alive was 32.5 months (range 0-96) in transverse rectus-abdominis musculo cutaneous flap group, and 18 months (range 8-41) in fasciocutaneous flap group. At the end of the follow-up, 10 patients were alive without evidence of disease and three patients developed metastatic lesion or local recurrence. The longest recorded disease free interval for a patient still alive and tumor free was 96 months. Only three patients (11%) had local complications: two wound infections and one partial necrosis of the transverse rectus-abdominis musculo cutaneous flap. Median hospital stay was 7 days (range 3-13) for transverse rectus-abdominis musculo cutaneous and 6 days (range 3-13) for fasciocutaneous flap. Our results confirmed that transverse rectus-abdominis musculo cutaneous group and fasciocutaneous flap flaps are good reconstructive options in patients with extended locally advanced breast cancer. Quality of life has improved in this group of patients, with acceptable survival periods and in some cases very important survival rates.     

应用邻近扩张皮瓣修复T4期局部晚期乳腺癌术中大面积软组织缺损的临床研究

目的在皮肤累及较大的局部晚期乳腺癌根治术中应用邻近扩张皮瓣修复胸壁大面积缺损,减少术后并发症,降低局部复发率。方法 64例新辅助化疗完全缓解(complete remission,CR)、部分缓解(partial remission,PR)的患者,在新辅助化疗同期行患侧乳房周围皮下扩张器置入术,并持续液压扩张皮肤至化疗结束,行乳腺癌根治术同期取扩张器,推进扩张皮瓣修复创面。37例同期游离植皮修复患者为对照组。结果 64例采用扩张皮瓣的患者术后伤口全部一期愈合,术后放疗未出现皮肤放射性溃疡,随访3年局部复发率明显低于游离植皮组。结论对于新辅助化疗有效的T4期乳腺癌患者,根治术中应用邻近扩张皮瓣修复可减少皮瓣坏死和放射性溃疡的发生,降低局部复发率。     

急诊动脉栓塞术在产后出血中的应用

目的　评价急诊经导管动脉栓塞术 (TAE)治疗难治性产后出血的疗效及安全性。方法　 18例难治性产后出血选择性插管至双侧髂内动脉或子宫动脉 ,行数字减影血管造影 (DSA)明确出血原因、部位后 ,以直径 1～ 3mm明胶海绵颗粒栓塞。结果　插管成功率 10 0 % ,手术时间 3 0～ 60min ,平均 ( 4 5 .2± 4.8)min ,术后止血总有效率 10 0 %。术后随访 3～ 40个月 ,均无严重并发症发生 ,所有患者宫体按期复旧 ,转经后月经正常。结论　TAE创伤小 ,疗效快速肯定 ,术后短期及长期随访无严重并发症 ,对危及生命的产后出血是一种有效的治疗措施     

乳腺癌新辅助化疗动脉灌注途径与静脉途径的对比

目的探讨乳腺癌新辅助化疗动脉灌注途径和静脉途径化疗的有效性。方法收集92例乳腺癌患者,均采用多柔比星为主的联合化疗方案,其中动脉组44例,行肿瘤区域动脉灌注化疗,必要时栓塞肿瘤供血动脉;静脉组48例,使用外周静脉全身化疗。观察两组患者的近期临床疗效及长期生存率。结果动脉组近期临床疗效明显优于静脉组(P0.05),但长期生存期率两组间差异无统计学意义(P0.05)。结论动脉灌注化疗可作为乳腺癌新辅助化疗的有效途径之一。     

Omental transposition in the treatment of locally advanced and recurrent breast cancer

An analysis was carried out of 43 patients treated by omental transposition for locoregional problems associated with breast cancer. Indications for surgery included advanced primary tumour (five), locally recurrent tumour (32), radiation induced sarcoma (two), and radionecrosis (four). Tumours were typically extensive (mean diameter 7.2 cm) and skin ulceration affected 30 patients. Other treatment modalities had been exhausted. Surgical excision followed by reconstruction using transposed omentum resulted in worthwhile local control and symptom relief in 31 patients (median duration 22 months). Chest wall disease rapidly recurred peripheral to the omental graft in 12 patients. On multiple regression analysis, duration of local control was significantly related to tumour diameter, ulceration, and earlier radioresistance (hazard ratios 15.8, 3.8 and 14.8 respectively). Survival (median 21, range from 1.5 to 122 months) correlated with tumour size, previous chemotherapy, and early re-recurrence (hazard ratios 7.2, 3.0 and 4.3). Omental transfer is a reliable method of restoring epithelial cover after radical surgery and is particularly useful after previous irradiation injury. In advanced and recurrent breast cancer, an aggressive surgical approach significantly improved the quality of life of most patients, but careful case selection is required to avoid inappropriate surgery for irremediable tumours.